Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...
Key Highlights:Pivot continues to progress toward CE Mark certification in 2026Stage 1 ISO Audit completed with Stage 2 planned for...
The industry-leading 503B outsourcing facility grows its footprint to 49 states, offering expanded healthcare resources with a spotlight on MississippiORLANDO,...
SAN JOSE, CALIFORNIA / ACCESS Newswire / October 28, 2025 / VSee Health, Inc. (Nasdaq:VSEE) (the "Company"), announced it has...
Accreditation for its lifestyle and disease management interventions complements Sharecare's existing three-year NCQA accreditations for Population Health Program and Case...
ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors...
ZIONSVILLE, IN / ACCESS Newswire / October 28, 2025 / WellBridge Surgical ("WellBridge") is delighted to announce two major milestones...
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company...
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical...
Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024,...
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Global functional gummy supplements market projected to surpass $50 billion by 2030 - CBDL expands into two of the fastest-growing...
Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has...
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Vancouver, Canada, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in...
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to...
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel...
MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), in cooperation with its...